AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
The Cooper Companies 2025 Q2 Earnings Revenue Grows 6.3% Amid EPS Decline
Generated by AI AgentAinvest Earnings Report Digest
Saturday, May 31, 2025 1:10 am ET2min read
The (COO) reported its fiscal 2025 Q2 earnings on May 30th, 2025. Revenue for the quarter rose 6.3% to $1 billion, surpassing analysts' expectations. However, the company's EPS fell short of expectations, declining slightly from the previous year. The company adjusted its full-year revenue guidance upwards, reflecting confidence in its growth trajectory. The earnings report showcased mixed results, with revenue growth but a decline in EPS.
Revenue
In 2025 Q2, experienced a revenue increase, reaching $1 billion, up from $942.60 million in the same quarter the previous year. CooperVision contributed significantly with $669.60 million in revenue, including $328.40 million from Toric and multifocal lenses. CooperSurgical added $332.70 million, with $205.80 million from office and surgical sales and $126.90 million from fertility services. The Sphere and other segments reported $341.20 million in revenue.
Earnings/Net Income
The Cooper Companies saw its EPS decline by 2.2% to $0.44 in 2025 Q2, compared to $0.45 in 2024 Q2. The company's net income also decreased slightly to $87.70 million, a 1.3% drop from $88.90 million in the previous year. The decline in EPS reflects challenges faced this quarter.
Price Action
The stock price of The Cooper Companies fell 5.14% during the latest trading day. Over the past week, it dropped 13.90%, and month-to-date, it has seen a decline of 16.96%.
Post-Earnings Price Action Review
The strategy of purchasing Cooper Companies' stock following a revenue beat and holding for 30 days yielded a 7.14% return, which was significantly below the benchmark by 26.93%. The strategy faced a substantial maximum drawdown of 36.10%, indicating high risk and moderate returns. The Sharpe ratio of 0.16 further highlighted the strategy's risk profile, suggesting that investors endured significant volatility for relatively modest returns. This performance suggests caution when employing this strategy, as the associated risks may outweigh the potential benefits. Investors should consider these factors when evaluating their approach to trading Cooper Companies' stock in response to earnings announcements.
CEO Commentary
Al White, President and Chief Executive Officer, stated that the company experienced a solid quarter with consolidated organic revenue growth of 7%, driven by double-digit growth in daily silicone hydrogel lenses at CooperVision and the office and surgical portfolio at CooperSurgical. He acknowledged challenges from a complex global operating environment but emphasized the company's strong execution in taking market share and launching new products. White expressed optimism about the MyDay and MySight portfolios, noting strong fitting activity and demand, while maintaining a cautious stance regarding the reduced market growth expectations in contact lenses and fertility due to economic pressures.
Guidance
The Cooper Companies is tightening and raising its revenue guidance to approximately $4.11 billion to $4.15 billion, reflecting a 5.5% to 6.5% increase. CooperVision's revenue guidance is now $2.76 billion to $2.79 billion, up 6% to 7% organically, while CooperSurgical's range is $1.35 billion to $1.36 billion, indicating 3.5% to 4.5% organic growth. Non-GAAP EPS guidance is raised to $4.05 to $4.11, representing a growth of approximately 10% to 11.5% year-over-year.
Additional News
In recent weeks, The Cooper Companies has made significant strides beyond its earnings report. On April 30, 2025, the company announced the appointment of Barbara Carbone to its Board of Directors, bringing her extensive expertise to their leadership team. Additionally, CooperCompanies is set to participate in the William Blair Growth Stock Conference, scheduled for May 8, 2025, showcasing its commitment to engaging with investors and highlighting growth strategies. These developments reflect the company's focus on strengthening its leadership and communicating its strategic vision to the investment community.
Revenue
In 2025 Q2, experienced a revenue increase, reaching $1 billion, up from $942.60 million in the same quarter the previous year. CooperVision contributed significantly with $669.60 million in revenue, including $328.40 million from Toric and multifocal lenses. CooperSurgical added $332.70 million, with $205.80 million from office and surgical sales and $126.90 million from fertility services. The Sphere and other segments reported $341.20 million in revenue.
Earnings/Net Income
The Cooper Companies saw its EPS decline by 2.2% to $0.44 in 2025 Q2, compared to $0.45 in 2024 Q2. The company's net income also decreased slightly to $87.70 million, a 1.3% drop from $88.90 million in the previous year. The decline in EPS reflects challenges faced this quarter.
Price Action
The stock price of The Cooper Companies fell 5.14% during the latest trading day. Over the past week, it dropped 13.90%, and month-to-date, it has seen a decline of 16.96%.
Post-Earnings Price Action Review
The strategy of purchasing Cooper Companies' stock following a revenue beat and holding for 30 days yielded a 7.14% return, which was significantly below the benchmark by 26.93%. The strategy faced a substantial maximum drawdown of 36.10%, indicating high risk and moderate returns. The Sharpe ratio of 0.16 further highlighted the strategy's risk profile, suggesting that investors endured significant volatility for relatively modest returns. This performance suggests caution when employing this strategy, as the associated risks may outweigh the potential benefits. Investors should consider these factors when evaluating their approach to trading Cooper Companies' stock in response to earnings announcements.
CEO Commentary
Al White, President and Chief Executive Officer, stated that the company experienced a solid quarter with consolidated organic revenue growth of 7%, driven by double-digit growth in daily silicone hydrogel lenses at CooperVision and the office and surgical portfolio at CooperSurgical. He acknowledged challenges from a complex global operating environment but emphasized the company's strong execution in taking market share and launching new products. White expressed optimism about the MyDay and MySight portfolios, noting strong fitting activity and demand, while maintaining a cautious stance regarding the reduced market growth expectations in contact lenses and fertility due to economic pressures.
Guidance
The Cooper Companies is tightening and raising its revenue guidance to approximately $4.11 billion to $4.15 billion, reflecting a 5.5% to 6.5% increase. CooperVision's revenue guidance is now $2.76 billion to $2.79 billion, up 6% to 7% organically, while CooperSurgical's range is $1.35 billion to $1.36 billion, indicating 3.5% to 4.5% organic growth. Non-GAAP EPS guidance is raised to $4.05 to $4.11, representing a growth of approximately 10% to 11.5% year-over-year.
Additional News
In recent weeks, The Cooper Companies has made significant strides beyond its earnings report. On April 30, 2025, the company announced the appointment of Barbara Carbone to its Board of Directors, bringing her extensive expertise to their leadership team. Additionally, CooperCompanies is set to participate in the William Blair Growth Stock Conference, scheduled for May 8, 2025, showcasing its commitment to engaging with investors and highlighting growth strategies. These developments reflect the company's focus on strengthening its leadership and communicating its strategic vision to the investment community.
Ainvest Earnings Report Digest
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Electrovaya 2025 Q4 Earnings Record Net Income Surges 1896.5% from Loss
Dec.20 2025
Winnebago Industries 2026 Q1 Earnings Record Revenue and 205.8% Net Income Turnaround
Dec.19 2025
Paychex 2026 Q2 Earnings Beats Revenue Estimates, EPS Falls Short
Dec.19 2025
Lamb Weston Holdings 2026 Q2 Earnings 272% Net Income Surge and 1.1% Revenue Growth
Dec.19 2025
ConAgra Brands 2026 Q2 Earnings Sharp Net Loss Amid Revenue Decline and EPS Drop
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet